Skip to main content
. 2022 Jun 8;41(10):3035–3047. doi: 10.1007/s10067-022-06218-8

Fig. 2.

Fig. 2

Psoriasis skin lesions and nail involvement. A PASI 75, B PASI 90, C PASI 100, D NAPSI (0) % response, and E NAPSI mean change from baseline in patients with PsA and treatment with ixekizumab Q4W and either ixekizumab monotherapy or consistenta concomitant MTX or any csDMARD (including MTX) through three years (156 weeks)